Are you Dr. Ingenito?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 41 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1023 Quincy Ave
Scranton, PA 18510Phone+1 310-279-7749
Summary
- Dr. Gary Ingenito, MD is a neurologist in Scranton, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
University of Miami/Jackson Health SystemResidency, Neurology, 1986 - 1989- University of Miami/Jackson Health SystemResidency, Neurological Surgery, 1984 - 1986
- University of Miami/Jackson Health SystemInternship, Transitional Year, 1983 - 1984
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1983
Certifications & Licensure
PA State Medical License 1991 - 2024
Clinical Trials
- Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG Start of enrollment: 2018 Apr 18
Publications & Presentations
PubMed
- 434 citationsEfficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.John M. Kane, William H. Carson, A. Saha, Robert D. McQuade, Gary G. Ingenito
The Journal of Clinical Psychiatry. 2002-09-23 - 337 citationsA placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.Paul E. Keck, Ronald N. Marcus, Stavros Tourkodimitris, Mirza Ali, Amy Liebeskind
The American Journal of Psychiatry. 2003-09-01 - 228 citationsEfficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.Siegfried Kasper, Mark N. Lerman, Robert D. McQuade, A. Saha, William H. Carson
The International Journal of Neuropsychopharmacology. 2003-12-01
Press Mentions
Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to Be Presented at the Upcoming American Academy of Neurology 2023 Annual MeetingApril 20th, 2023- Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic EpilepsiesMarch 8th, 2023
- Catalyst Pharmaceuticals’ Firdapse® (Amifampridine Phosphate) Receives Marketing Approval in Canada for Patients with LEMSAugust 6th, 2020
- Join now to see all
